, Hormonothérapie La place de l'hormonothérapie dans le cancer de l'endomètre métastatique n'est pas bien identifiée

. Boglioli, Deux types d'approches sont possibles, notamment en cas de situation palliative. L'utilisation d'agents progestatifs de type mégestrol notamment ou d'une action anti-estrogène par inhibiteurs de l'aromatase, 2016.

, Bibliographie

@. Agarwal, R. Kaye, and S. , Ovarian cancer: strategies for overcoming resistance to chemotherapy, Nature Reviews Cancer, vol.19, issue.Suppl. 9, pp.502-518, 2003.
DOI : 10.1200/JCO.2002.03.038

C. @bullet-aghajanian, S. Blank, B. Goff, P. Judson, M. Teneriello et al., OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, Journal of Clinical Oncology, vol.30, issue.17, pp.2039-2084, 2012.
DOI : 10.1200/JCO.2012.42.0505

C. @bullet-aghajanian, M. Sill, K. Darcy, B. Greer, D. Mcmeekin et al., Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study, Journal of Clinical Oncology, vol.29, issue.16, pp.2259-65, 2011.
DOI : 10.1200/JCO.2010.32.6397

@. Ahmed, A. Etemadmoghadam, D. Temple, J. Lynch, A. Riad et al., Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary, The Journal of Pathology, vol.99, issue.1, pp.49-56, 2010.
DOI : 10.1073/pnas.202610899

M. @bullet-alexander and S. Leeman, Estrogen-inducible neurotensin immunoreactivity in the preoptic area of the female rat, The Journal of Comparative Neurology, vol.131, issue.4, pp.496-509, 1994.
DOI : 10.1161/01.HYP.4.6.888

M. @bullet-alexander, Estrogen-regulated synthesis of neurotensin in neurosecretory cells of the hypothalamic arcuate nucleus in the female rat., Endocrinology, vol.133, issue.4, pp.1809-1825, 1993.
DOI : 10.1210/endo.133.4.8404623

M. @bullet-alifano, F. Souazé, S. Dupouy, S. Camilleri-broët, M. Younes et al., Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res, pp.4401-4411, 2010.

A. @bullet-alkushi, P. Lim, A. Coldman, D. Huntsman, D. Miller et al., Interpretation of p53 Immunoreactivity in Endometrial Carcinoma: Establishing a Clinically Relevant Cut-Off Level, International Journal of Gynecological Pathology, vol.23, issue.2, pp.129-166, 2004.
DOI : 10.1097/00004347-200404000-00007

F. @bullet-alshoukr, A. Prignon, L. Brans, A. Jallane, S. Mendes et al., Novel DOTAneurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors

, Bioconjug Chem, vol.22, issue.7, pp.1374-85, 2011.

@. Alvarez, T. Miller, E. Duska, L. Oliva, and E. , Molecular Profile of Grade 3 Endometrioid Endometrial Carcinoma, The American Journal of Surgical Pathology, vol.36, issue.5, pp.753-61
DOI : 10.1097/PAS.0b013e318247b7bb

@. Amar, S. Kitabgi, P. Vincent, and J. , Activation of phosphatidylinositol turnover by neurotensin receptors in the human colonic adenocarcinoma cell line HT29, FEBS Letters, vol.347, issue.1, pp.31-37, 1986.
DOI : 10.1016/0006-8993(85)90184-2

@. Amorino, G. Deeble, P. Parsons, and S. , Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway, Oncogene, vol.279, issue.Suppl, pp.745-56, 2006.
DOI : 10.1074/jbc.M401453200

@. Anglesio, M. Carey, M. Köbel, M. Mackay, H. Huntsman et al., Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010, Gynecologic Oncology, vol.121, issue.2, pp.407-422, 2010.
DOI : 10.1016/j.ygyno.2011.01.005

@. Anglesio, M. Kommoss, S. Tolcher, M. , C. B. Galletta et al.,

J. Gamez, A. Tinker, D. Bowtell, D. Huntsman, C. Gilks et al., Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19 % of carcinomas, J Pathol, 2013.

@. Antoniou, A. Pharoah, P. Narod, S. Risch, H. Eyfjord et al., Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies, The American Journal of Human Genetics, vol.72, issue.5, pp.1117-1147, 2003.
DOI : 10.1086/375033

@. Armstrong, M. Parker, M. Ferris, C. Leeman, and S. , Neurotensin stimulates [3H]oleic acid translocation across rat small intestine, American Journal of Physiology-Gastrointestinal and Liver Physiology, vol.251, issue.6, pp.823-832, 1986.
DOI : 10.1152/ajpgi.1986.251.6.G823

@. Aronica, S. Kraus, W. Katzenellenbogen, and B. , Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription., Proceedings of the National Academy of Sciences, vol.91, issue.18, pp.8517-8538, 1994.
DOI : 10.1073/pnas.91.18.8517

@. Arts-de-jong, M. De-bock, G. Van-asperen, C. Mourits, M. De-hullu et al., Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review, European Journal of Cancer, vol.61, pp.137-182, 2016.
DOI : 10.1016/j.ejca.2016.03.009

@. Ashworth and A. , A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair, Journal of Clinical Oncology, vol.26, issue.22, 2008.
DOI : 10.1200/JCO.2008.16.0812

@. Ba?a, I. Schmidt-gayk, and H. , Neurotensin and medullary carcinoma of the thyroid gland, Journal of Cancer Research and Clinical Oncology, vol.77, issue.2, pp.229-259, 1981.
DOI : 10.1007/BF00403370

@. Barry, J. Azizia, M. Hardiman, and P. , Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis, Human Reproduction Update, vol.18, issue.5, pp.748-58, 2014.
DOI : 10.1097/CEJ.0b013e328329d830

@. Bean, A. Dagerlind, A. Hökfelt, T. Dobner, and P. , Cloning of human neurotensin/neuromedin n genomic sequences and expression in the ventral mesencephalon of schizophrenics and age/sex matched controls, Neuroscience, vol.50, issue.2, 1992.
DOI : 10.1016/0306-4522(92)90421-W

@. Bergman, L. Beelen, M. Gallee, M. Hollema, H. Benraadt et al., Risk and prognosis of endometrial cancer after tamoxifen for breast cancer, The Lancet, vol.356, issue.9233, pp.881-888, 2000.
DOI : 10.1016/S0140-6736(00)02677-5

@. Bhoola, S. Hoskins, and W. , Diagnosis and Management of Epithelial Ovarian Cancer, Obstetrics & Gynecology, vol.107, issue.6, pp.1399-410, 2006.
DOI : 10.1097/01.AOG.0000220516.34053.48

@. Blackburn, A. Fletcher, D. Adrian, T. Bloom, and S. , Neurotensin Infusion in Man: Pharmacokinetics and Effect on Gastrointestinal and Pituitary Hormones*, The Journal of Clinical Endocrinology & Metabolism, vol.51, issue.6, pp.1257-61, 1980.
DOI : 10.1210/jcem-51-6-1257

@. Bochman, M. Schwacha, and A. , The Mcm Complex: Unwinding the Mechanism of a Replicative Helicase, Microbiology and Molecular Biology Reviews, vol.73, issue.4, pp.652-83, 2009.
DOI : 10.1128/MMBR.00019-09

@. Bogliolo, S. Cassani, C. Gardella, B. Musacchi, V. Babilonti et al., Current opinion on bevacizumab on endometrial cancer treatment, Expert Opinion on Biological Therapy, vol.60, issue.19, pp.299-307, 2014.
DOI : 10.1093/annonc/mdn637

@. Bogliolo, S. Gardella, B. Dominoni, M. Musacchi, V. Cassani et al., Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma, Archives of Gynecology and Obstetrics, vol.33, issue.8, pp.701-709, 2015.
DOI : 10.1200/JCO.2014.58.3401

T. Bonome, J. Lee, D. Park, M. Radonovich, C. Pise-masison et al., Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary, Cancer Research, vol.65, issue.22, pp.10602-10614, 2005.
DOI : 10.1158/0008-5472.CAN-05-2240

@. Boules, M. Li, Z. Smith, K. Fredrickson, P. Richelson et al., Diverse roles of neurotensin agonists in the central nervous system. Front Endocrinol (Lausanne), 2013.

@. Bozou, J. Rochet, N. Magnaldo, I. Vincent, J. Kitabgi et al., Neurotensin stimulates inositol trisphosphate-mediated calcium mobilization but not protein kinase C activation in HT29 cells. Involvement of a G-protein, Biochemical Journal, vol.264, issue.3, 1989.
DOI : 10.1042/bj2640871
URL : http://europepmc.org/articles/pmc1133666?pdf=render

, Dec, vol.15264, issue.3, pp.871-879

L. @bullet-brinton, L. Sakoda, J. Lissowska, M. Sherman, N. Chatterjee et al., Reproductive risk factors for endometrial cancer among Polish women, British Journal of Cancer, vol.151, issue.9, pp.1450-1456, 2007.
DOI : 10.1002/ijc.11598

@. Brook, C. Shulkes, A. Sewell, R. Smallwood, and R. , Hepatic metabolism of neurotensin. Endocrinology, 1987.

@. Brun, J. Cortez, A. Donnadieu, A. Bazot, M. Driguez et al., Pathologie tumorale endom??triale b??nigne et l??sions fronti??res de l'endom??tre, EMC - Gyn??cologie, vol.5, issue.2, pp.10-1016
DOI : 10.1016/S0246-1064(10)45875-2

P. @bullet-brun, C. Mastrotto, E. Beggiao, A. Stefani, L. Barzon et al., Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation, American Journal of Physiology-Gastrointestinal and Liver Physiology, vol.288, issue.4, pp.621-630, 2005.
DOI : 10.1016/0026-2862(90)90024-L

@. Bruno, S. Darzynkiewicz, and Z. , Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells, Cell Proliferation, vol.92, issue.1, pp.31-40, 1992.
DOI : 10.1002/1097-0142(19900301)65:5<1130::AID-CNCR2820650516>3.0.CO;2-A

@. Burger, R. Brady, M. Bookman, M. Fleming, G. Monk et al., Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer, New England Journal of Medicine, vol.365, issue.26, pp.2473-83, 1056.
DOI : 10.1056/NEJMoa1104390

, Integrated genomic analyses of ovarian carcinoma, Nature, vol.474, issue.7353, pp.609-624, 2011.

@. Carraway, R. Leeman, and S. , The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami, J Biol Chem, vol.248, pp.6854-61, 1973.

@. Castagliuolo, I. Wang, C. Valenick, L. Pasha, A. Nikulasson et al., Neurotensin is a proinflammatory neuropeptide in colonic inflammation, Journal of Clinical Investigation, vol.103, issue.6, pp.843-852, 1999.
DOI : 10.1172/JCI4217
URL : http://www.jci.org/articles/view/4217/files/pdf

@. Chabry, J. Botto, J. Nouel, D. Beaudet, A. Vincent et al., Thr-422 and Tyr-424 Residues in the Carboxyl Terminus Are Critical for the Internalization of the Rat Neurotensin Receptor, Journal of Biological Chemistry, vol.39, issue.6, pp.2439-2481, 1995.
DOI : 10.1073/pnas.87.17.6507

@. Chakravarty, D. Gupta, N. Goda, J. Srinivasan, R. Patel et al., Steroid receptors, HER2/neu and Ki-67, in endometrioid type of endometrial carcinoma: Correlation with conventional histomorphological features of prognosis, Acta Histochemica, vol.112, issue.4
DOI : 10.1016/j.acthis.2009.03.001

, Acta Histochem, vol.112, issue.4, pp.355-63, 2010.

@. Chen, J. Kuo, S. Liaw, Y. Avital, I. Stojadinovic et al., Endometrial Cancer Incidence in Breast Cancer Patients Correlating with Age and Duration of Tamoxifen Use: a Population Based Study, Journal of Cancer, vol.5, issue.2, pp.151-156, 2014.
DOI : 10.7150/jca.8412

@. Chong, J. Mahbubani, H. Khoo, C. Blow, and J. , Purification of an MCM-containing complex as a component of the DNA replication licensing system, Nature, vol.375, issue.6530, pp.418-439, 1995.
DOI : 10.1038/375418a0

D. Church, S. Briggs, C. Palles, E. Domingo, S. Kearsey et al., DNA polymerase ?? and ?? exonuclease domain mutations in endometrial cancer, Human Molecular Genetics, vol.11, issue.14, pp.2820-2828, 2013.
DOI : 10.1186/gb-2010-11-8-r86
URL : https://academic.oup.com/hmg/article-pdf/22/14/2820/17259128/ddt131.pdf

@. Ciancio, N. Galasso, M. Campisi, R. Bivona, L. Migliore et al., Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer, Multidisciplinary Respiratory Medicine, vol.7, issue.1, p.29, 2012.
DOI : 10.1186/2049-6958-7-29

, Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies, PLoS Med, vol.20129, issue.4, 2012.

, Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies, Lancet Oncol. 2015, vol.16, issue.9, pp.1061-1070, 2015.

@. Colombo, N. Creutzberg, C. Amant, F. Bosse, T. González-martín et al., ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer, International Journal of Gynecological Cancer, vol.26, issue.1, pp.2-30, 2016.
DOI : 10.1097/IGC.0000000000000609
URL : http://europepmc.org/articles/pmc4679344?pdf=render

@. Cook, L. Pestak, C. Leung, A. Steed, H. Nation et al., Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk, British Journal of Cancer, vol.15, issue.2, pp.265-269, 2016.
DOI : 10.1002/cncr.29321
URL : https://www.nature.com/articles/bjc2016400.pdf

M. @bullet-cuatrecasas, A. Villanueva, X. Matias-guiu, and J. Prat, K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer, pp.1581-1587, 1997.

R. @bullet-de-angelis, M. Sant, M. Coleman, S. Francisci, P. Baili et al., Cancer survival in Europe 1999???2007 by country and age: results of EUROCARE-5???a population-based study, The Lancet Oncology, vol.15, issue.1, pp.23-34, 2013.
DOI : 10.1016/S1470-2045(13)70546-1

@. Degolier, T. Duke, G. Carraway, and R. , Neurotensin decreases pepsin output and gastrointestinal motility in chickens, Poultry Science, vol.76, issue.10
DOI : 10.1093/ps/76.10.1435
URL : https://academic.oup.com/ps/article-pdf/76/10/1435/4446846/poultrysci76-1435.pdf

, Poult Sci, vol.76, issue.10, pp.1435-1444, 1997.

@. Disaia, P. Tewari, and K. , Recent Advancements in the Treatment of Epithelial Ovarian Cancer, Journal of Obstetrics and Gynaecology Research, vol.5, issue.Suppl 7, 2001.
DOI : 10.1038/bjc.1998.710

@. Djordjevic, B. Barkoh, B. Luthra, R. Broaddus, and R. , Relationship between PTEN, DNA mismatch repair and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas, Modern Pathology, vol.228, issue.10, 2013.
DOI : 10.1016/j.ajog.2004.01.017

@. Dobner, P. Barber, D. Villa-komaroff, L. Mckiernan, and C. , Cloning and sequence analysis of cDNA for the canine neurotensin/neuromedin N precursor., Proceedings of the National Academy of Sciences, vol.84, issue.10, pp.3516-3536, 1987.
DOI : 10.1073/pnas.84.10.3516

@. Dossus, L. Allen, N. Kaaks, R. Bakken, K. Lund et al., Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition, International Journal of Cancer, vol.13, issue.2, pp.442-51, 2010.
DOI : 10.1016/S0002-9378(11)91709-8
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.25050

J. Drewe, S. Mihailovic, D. Amato, M. Beglinger, and C. , Regulation of Fat-Stimulated Neurotensin Secretion in Healthy Subjects, The Journal of Clinical Endocrinology & Metabolism, vol.93, issue.5
DOI : 10.1210/jc.2007-2238

, J Clin Endocrinol Metab, vol.93, issue.5, pp.1964-70, 2008.

@. Du-bois, A. Lück, H. Meier, W. Adams, H. Möbus et al., A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer, CancerSpectrum Knowledge Environment, vol.95, issue.17, pp.1320-1329, 2003.
DOI : 10.1093/jnci/djg036

S. @bullet-du-manoir, P. Guillaud, E. Camus, D. Seigneurin, and G. Brugal, Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment, Cytometry, vol.82, issue.5, pp.455-63, 1991.
DOI : 10.1002/hon.2900020406

@. Duchrow, M. Schlüter, C. Wohlenberg, C. Flad, H. Gerdes et al., Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67, Cell Proliferation, vol.3, issue.1, pp.1-12, 1996.
DOI : 10.1093/nar/18.23.7119

@. Dupouy, S. Doan, V. Wu, Z. Mourra, N. Liu et al., Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice, Oncotarget, vol.5, issue.18, pp.8235-51, 2014.
DOI : 10.18632/oncotarget.1632

@. Dupouy, S. Mourra, N. Doan, V. Gompel, A. Alifano et al., The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers, Biochimie, vol.93, issue.9
DOI : 10.1016/j.biochi.2011.04.024

, Biochimie, vol.93, issue.9, pp.1369-78, 2011.

@. Dupouy, S. Viardot-foucault, V. Alifano, M. Souazé, F. Plu-bureau et al., The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression, PLoS ONE, vol.272, issue.1, 2009.
DOI : 10.1371/journal.pone.0004223.t004

@. Ehrenfried, J. Zhou, Z. Thompson, J. Evers, and B. , Expression of the Neurotensin Gene in Fetal Human Liver and Fibrolamellar Carcinoma, Annals of Surgery, vol.220, issue.4, pp.484-493, 1994.
DOI : 10.1097/00000658-199410000-00007

@. Elek, J. Pinzon, W. Park, K. Narayanan, and R. , Relevant genomics of neurotensin receptor in cancer, Anticancer Res, 2000.

. Jan-feb, , pp.53-61

@. Evers, B. Wang, X. Zhou, Z. Townsend, C. Jr et al., Characterization of promoter elements required for cell-specific expression of the neurotensin/neuromedin N gene in a human endocrine cell line., Molecular and Cellular Biology, vol.15, issue.7, 1995.
DOI : 10.1128/MCB.15.7.3870

@. Evers and B. , Neurotensin and growth of normal and neoplastic tissues. Peptides, pp.2424-2457, 2006.

@. Faber, M. Kjaer, S. Dehlendorff, C. Chang-claude, J. Andersen et al., Australian Cancer Study (Ovarian Cancer) Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies. Cancer Causes Control, pp.989-1004, 2013.

@. Féliciangéli, S. Kitabgi, and P. , Insertion of Dibasic Residues Directs a Constitutive Protein to the Regulated Secretory Pathway, Biochemical and Biophysical Research Communications, vol.290, issue.1
DOI : 10.1006/bbrc.2001.6137

, Biochem Biophys Res Commun, vol.290, issue.1, pp.191-197, 2002.

@. Ferlay, J. Soerjomataram, I. Dikshit, R. Eser, S. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, International Journal of Cancer, vol.13, issue.5, pp.359-86, 2009.
DOI : 10.1016/S1470-2045(12)70137-7

@. Ferris, C. George, J. Eastwood, G. Potegal, M. Carraway et al., Plasma levels of human neurotensin: Methodological and physiological considerations, Peptides, vol.12, issue.2, pp.215-235, 1991.
DOI : 10.1016/0196-9781(91)90002-7

G. Fleming, V. Brunetto, D. Cella, K. Look, G. Reid et al.,

, Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study, J Clin Oncol, vol.22, issue.11, pp.2159-66, 2004.

@. Fleming, N. Soliman, P. Westin, S. Dos-reis, R. Munsell et al.,

, Int J Gynecol Cancer, vol.25, issue.8, pp.1437-1481, 2015.

@. Fournier, A. Dossus, L. Mesrine, S. Vilier, A. Boutron-ruault et al., Risks of Endometrial Cancer Associated With Different Hormone Replacement Therapies in the E3N Cohort, 1992-2008, American Journal of Epidemiology, vol.15, issue.2, pp.508-525, 2009.
DOI : 10.1097/gme.0b013e3181334b6c

@. Friry, C. Feliciangeli, S. Richard, F. Kitabgi, P. Rovere et al., Production of recombinant large proneurotensin/neuromedin Nderived peptides and characterization of their binding and biological activity, Biochem Biophys Res Commun. Feb, vol.1290, issue.4, pp.1161-1169, 2002.
DOI : 10.1006/bbrc.2001.6308

@. Fung-kee-fung, M. Dodge, J. Elit, L. Lukka, H. Chambers et al., Follow-up after primary therapy for endometrial cancer: A systematic review, Gynecologic Oncology, vol.101, issue.3, pp.520-529, 2006.
DOI : 10.1016/j.ygyno.2006.02.011

@. Gailly, P. Najimi, M. Hermans, and E. , Evidence for the dual coupling of the rat neurotensin receptor with pertussis toxin-sensitive and insensitive G-proteins, FEBS Letters, vol.273, issue.2-3, pp.109-122, 2000.
DOI : 10.1074/jbc.273.4.1951

@. Galaal, K. , A. Moundhri, M. Bryant, A. Lopes et al.,

C. Database and S. Rev, , 2014.

@. Gao, J. Aksoy, B. Dogrusoz, U. Dresdner, G. Gross et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, p.1, 2013.

@. Garg, K. Levine, D. Olvera, N. Dao, F. Bisogna et al., BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas, The American Journal of Surgical Pathology, vol.37, issue.1, pp.138-184, 2013.
DOI : 10.1097/PAS.0b013e31826cabbd

@. Gassel, A. Backe, J. Krebs, S. Schön, S. Caffier et al., Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome, Journal of Clinical Pathology, vol.51, issue.1, 1998.
DOI : 10.1136/jcp.51.1.25

@. Gauchotte, G. Hergalant, S. Vigouroux, C. Casse, J. Houlgatte et al., Cytoplasmic overexpression of RNA-binding protein HuR is a marker of poor prognosis in meningioma, and HuR knockdown decreases meningioma cell growth and resistance to hypoxia, The Journal of Pathology, vol.113, issue.2, pp.421-434, 2017.
DOI : 10.1002/cncr.23904
URL : https://hal.archives-ouvertes.fr/hal-01718786

@. Gauchotte, G. Vigouroux, C. Rech, F. Battaglia-hsu, S. Soudant et al., Expression of Minichromosome Maintenance MCM6 Protein in Meningiomas is Strongly Correlated With Histologic Grade and Clinical Outcome, The American Journal of Surgical Pathology, vol.36, issue.2, pp.283-91, 2012.
DOI : 10.1097/PAS.0b013e318235ee03

@. Gemignani, M. Schlaerth, A. Bogomolniy, F. Barakat, R. Lin et al., Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma, Gynecologic Oncology, vol.90, issue.2, pp.378-81, 2003.
DOI : 10.1016/S0090-8258(03)00264-6

@. Gerdes, J. Schwab, U. Lemke, H. Stein, and H. , Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation, International Journal of Cancer, vol.18, issue.1, pp.13-20, 1983.
DOI : 10.1177/28.8.7003001

C. Gerlach, D. Sakkab, T. Scholzen, R. Dassler, M. Alison et al., Ki-67 expression during rat liver regeneration after partial hepatectomy. Hepatol Baltim Md, pp.573-581, 1997.

@. Giangaspero, F. Burger, P. Budwit, D. Usellini, L. Mancini et al., Regulatory peptides in neuronal neoplasms of the central nervous system, Clin Neuropathol, vol.4, issue.3, pp.111-116, 1985.

@. Gillatt, D. Shulkes, A. Read, D. Hardy, and K. , Metabolism of neurotensin by isolated perfused rat kidney, American Journal of Physiology-Endocrinology and Metabolism, vol.53, issue.6, pp.930-936, 1990.
DOI : 10.1161/01.RES.47.1.1

@. Giorgi, R. Chile, T. Bello, A. Reyes, R. Fortes et al., Expression of Neurotensin and its Receptors in Pituitary Adenomas, Journal of Neuroendocrinology, vol.12, issue.9, 2008.
DOI : 10.1177/26.4.207771

@. Go, R. Adjei, and A. , Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin, Journal of Clinical Oncology, vol.17, issue.1, pp.409-431, 1999.
DOI : 10.1200/JCO.1999.17.1.409

@. Gompel and A. , Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy, Climacteric, vol.46, issue.4, 2018.
DOI : 10.1111/j.1471-0528.2000.tb11654.x

@. Guha, S. Lunn, J. Santiskulvong, C. Rozengurt, and E. , Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res, pp.2379-87, 2003.

@. Guha, S. Rey, O. Rozengurt, and E. , Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res, pp.1632-1672, 2002.

@. Gui, X. Guzman, G. Dobner, P. Kadkol, and S. , Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides, pp.1609-1624, 2008.
DOI : 10.1016/j.peptides.2008.04.014

@. Gully, D. Labeeuw, B. Boigegrain, R. Oury-donat, F. Bachy et al., Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist, J Pharmacol Exp Ther Feb, vol.280, issue.2, pp.802-814, 1997.

@. Hammer, R. Leeman, S. Carraway, R. Williams, and R. , Isolation of human intestinal neurotensin, J Biol Chem, vol.255, issue.6, pp.2476-80, 1980.

@. Harada, E. Niiyama, M. Syuto, and B. , Hepatic bile and pancreatic exocrine secretions evoked by gastrointestinal peptides in sheep, Comparative Biochemistry and Physiology Part A: Physiology, vol.85, issue.4, pp.729-763, 1986.
DOI : 10.1016/0300-9629(86)90285-9

@. Harvey, C. Wang, Y. Darmoul, D. Phillips, A. Mantei et al., Characterisation of a human homologue of a yeast cell division cycle gene, MCM6, located adjacent to the 5??? end of the lactase gene on chromosome 2q21, FEBS Letters, vol.29, issue.2-3, pp.2-3135, 1996.
DOI : 10.1006/geno.1995.9951

@. Hassan, S. Dobner, P. Carraway, and R. , Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells, Regulatory Peptides, vol.120, issue.1-3, pp.1-3155, 2004.
DOI : 10.1016/j.regpep.2004.03.004

@. Helder-woolderink, J. Blok, E. Vasen, H. Hollema, H. Mourits et al., Ovarian cancer in Lynch syndrome; a systematic review, European Journal of Cancer, vol.55, pp.65-73, 2016.
DOI : 10.1016/j.ejca.2015.12.005

Y. @bullet-hiradate, H. Inoue, N. Kobayashi, Y. Shirakata, Y. Suzuki et al., Neurotensin enhances sperm capacitation and acrosome reaction in mice, Biol Reprod, vol.91, issue.2, 2014.

@. Hiraiwa, A. Fujita, M. Adachi, A. Ono, H. Nagasaka et al., Specific distribution patterns of hCDC47 expression in cutaneous diseases, Journal of Cutaneous Pathology, vol.73, issue.6, pp.285-90, 1998.
DOI : 10.1083/jcb.105.4.1549

A. Hiraiwa, M. Fujita, T. Nagasaka, A. Adachi, M. Ohashi et al., Immunolocalization of hCDC47 protein in normal and neoplastic human tissues and its relation to growth, International Journal of Cancer, vol.7, issue.2, pp.180-184, 1997.
DOI : 10.1016/0167-4781(96)00057-7
URL : http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0215(19970422)74:2<180::AID-IJC7>3.0.CO;2-V/pdf

@. Hsu, C. Bristow, R. Cha, M. Wang, B. Ho et al., Characterization of active mitogenactivated protein kinase in ovarian serous carcinomas. Clin Cancer Res, pp.6432-6438, 2004.

@. Inca, Cancer de l'endomètre ; rapport intégral, 2010.

@. Ishihara, M. Mukai, H. Nagai, S. Onozawa, M. Nihei et al., Retrospective Analysis of Risk Factors for Central Nervous System Metastases in Operable Breast Cancer: Effects of Biologic Subtype and Ki67 Overexpression on Survival, Oncology, vol.28, issue.3, pp.135-175, 2013.
DOI : 10.1200/JCO.2009.25.9820

@. Jelovac, D. Armstrong, and D. , Recent progress in the diagnosis and treatment of ovarian cancer, CA: A Cancer Journal for Clinicians, vol.113, issue.1, 2011.
DOI : 10.1016/j.ygyno.2009.01.012

@. Jones, S. Wang, T. , S. Iem, T. Mao et al., Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science, pp.228-259, 2010.

S. @bullet-kamimae, E. Yamamoto, M. Kai, T. Niinuma, H. Yamano et al., Epigenetic silencing of NTSR1 is associated with lateral and noninvasive growth of colorectal tumors, Oncotarget, vol.6, issue.30, pp.29975-90, 2015.

@. Kandoth, C. Schultz, N. Cherniack, A. Akbani, R. Liu et al., Integrated genomic characterization of endometrial carcinoma, Nature, vol.497, issue.7447, pp.67-73, 1038.

@. Kato, K. Toki, T. Shimizu, M. Shiozawa, T. Fujii et al., Expression of Replication-Licensing Factors MCM2 and MCM3 in Normal, Hyperplastic, and Carcinomatous Endometrium: Correlation With Expression of Ki-67 and Estrogen and Progesterone Receptors, International Journal of Gynecological Pathology, vol.22, issue.4, pp.334-374, 2003.
DOI : 10.1097/01.pgp.0000092129.10100.5e

@. Kim, H. Kim, T. Chung, H. Song, and Y. , Risk and prognosis of ovarian cancer in women with endometriosis: a metaanalysis, Br J Cancer Apr, vol.2110, issue.7, 2014.

@. Kim, J. Li, J. Song, J. Lee, E. Weiss et al., Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells, Oncotarget, vol.6, issue.29, pp.26960-70, 2015.

@. Kindelberger, D. Lee, Y. Miron, A. Hirsch, M. Feltmate et al., Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship, The American Journal of Surgical Pathology, vol.31, issue.2, pp.161-170, 2007.
DOI : 10.1097/01.pas.0000213335.40358.47

@. Kislauskis, E. Bullock, B. Mcneil, S. Dobner, and P. , The rat gene encoding neurotensin and neuromedin N. Structure, tissuespecific expression, and evolution of exon sequences, J Biol Chem, vol.263, issue.10, pp.4963-4971, 1988.

@. Kislauskis, E. Dobner, and P. , Mutually dependent response elements in the Cis-regulatory region of the neurotensin/neuromedin N gene integrate environmental stimuli in PC12 cells, Neuron, vol.4, issue.5, pp.783-95, 1990.
DOI : 10.1016/0896-6273(90)90205-T

@. Kitabgi, P. Carraway, R. Leeman, and S. , Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin, J Biol Chem, vol.251, issue.22, pp.7053-7061, 1976.

@. Kitabgi, P. Checler, F. Mazella, J. Vincent, and J. , Pharmacology and biochemistry of neurotensin receptors. Rev Clin Basic Pharm, pp.3-4397, 1985.

@. Kitabgi, P. , D. Nadai, F. Labbe-jullie, C. Dubuc et al., FUNCTIONAL AND PHARMACOLOGICAL ASPECTS OF CENTRAL NEUROPEPTIDERGIC TRANSMISSION MEDIATED BY NEUROTENSIN AND NEUROMEDIN N, Clinical Neuropharmacology, vol.15, pp.313-314, 1992.
DOI : 10.1097/00002826-199201001-00162

@. Kitabgi, P. Freychet, and P. , Effects of neurotensin on isolated intestinal smooth muscles, Eur J Pharmacol Aug, vol.1550, issue.4, pp.349-57, 1978.

@. Kitabgi and P. , Inactivation of neurotensin and neuromedin N by Zn metallopeptidases. Peptides, pp.2515-2537, 2006.

@. Kitabgi and P. , Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes, Curr Opin Drug Discov Devel, vol.5, issue.5, pp.764-76, 2002.

@. Kleczkowska, P. Lipkowski, and A. , Neurotensin and neurotensin receptors: Characteristic, structure???activity relationship and pain modulation???A review, European Journal of Pharmacology, vol.716, issue.1-3, 2013.
DOI : 10.1016/j.ejphar.2013.03.004

@. Köbel, M. Kalloger, S. Huntsman, D. Santos, J. Swenerton et al., Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC. Differences in tumor type in low-stage versus high-stage ovarian carcinomas, Int J Gynecol Pathol, 2010.

@. Koh, W. Abu-rustum, N. Bean, S. Bradley, K. Campos et al., Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network, vol.16, issue.2, pp.170-199, 2018.
DOI : 10.6004/jnccn.2018.0006

K. @bullet-konstantinos, S. Marios, M. Anna, K. Nikolaos, P. Efstratios et al., Expression of Ki-67 as proliferation biomarker in imprint smears of endometrial carcinoma, Diagn Cytopathol, vol.41, issue.3, pp.212-219, 2013.

@. Koushik, A. Grundy, A. Abrahamowicz, M. Arseneau, J. Gilbert et al., Hormonal and reproductive factors and the risk of ovarian cancer. Cancer Causes Control, pp.393-403, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01534637

@. Kubota, Y. Mimura, S. Nishimoto, S. Takisawa, H. Nojima et al., Identification of the yeast MCM3-related protein as a component of xenopus DNA replication licensing factor, Cell, vol.81, issue.4, pp.601-610, 1995.
DOI : 10.1016/0092-8674(95)90081-0

@. Kurman, R. , and S. Iem, Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer???Shifting the paradigm, Human Pathology, vol.42, issue.7, pp.918-949, 2011.
DOI : 10.1016/j.humpath.2011.03.003

@. Labib, K. Tercero, J. Diffley, and J. , Uninterrupted MCM2-7 Function Required for DNA Replication Fork Progression, Science, vol.288, issue.5471, pp.1643-1650, 2000.
DOI : 10.1126/science.288.5471.1643

@. Lavalle, C. George, K. Sharlow, E. Lazo, J. Wipf et al., Protein kinase D as a potential new target for cancer therapy, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1806, issue.2, pp.183-92, 2010.
DOI : 10.1016/j.bbcan.2010.05.003

J. @bullet-ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote et al., Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial, The Lancet Oncology, vol.15, issue.8, pp.852-61, 2014.
DOI : 10.1016/S1470-2045(14)70228-1

J. Lee and J. Hurwitz, Isolation and characterization of various complexes of the minichromosome maintenance proteins of Schizosaccharomyces pombe, J Biol Chem. Jun, vol.23275, issue.25, pp.18871-18879, 2000.

@. Levy-lahad, E. Friedman, and E. , Cancer risks among BRCA1 and BRCA2 mutation carriers, British Journal of Cancer, vol.91, issue.1, pp.11-16, 2007.
DOI : 10.1038/sj.bjc.6602239

J. @bullet-leyton, L. Garcia-marin, R. Jensen, and T. Moody, Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells, European Journal of Pharmacology, vol.442, issue.3, pp.179-86, 2002.
DOI : 10.1016/S0014-2999(02)01539-X

@. Li, S. Xue, W. Khoo, U. Ngan, H. Chan et al., Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis, Histopathology, vol.442, issue.3, pp.307-320, 2005.
DOI : 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D

@. Lim, D. Oliva, and E. , Precursors and pathogenesis of ovarian carcinoma, Pathology, vol.45, issue.3, pp.229-271
DOI : 10.1097/PAT.0b013e32835f2264

@. Luttinger, D. King, R. Sheppard, D. Strupp, J. Nemeroff et al., The effect of neurotensin on food consumption in the rat, European Journal of Pharmacology, vol.81, issue.3, pp.499-503, 1982.
DOI : 10.1016/0014-2999(82)90116-9

@. Lynch, H. Casey, M. Snyder, C. Bewtra, C. Lynch et al., Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management, Molecular Oncology, vol.98, issue.Suppl. 1, pp.97-137, 2009.
DOI : 10.1016/S0301-2115(01)00318-9

@. Maccallum, D. Hall, and P. , The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle, The Journal of Pathology, vol.26, issue.5, pp.537-581, 2000.
DOI : 10.1042/bj2100183

@. Mailleux, P. Przedborski, S. Beaumont, A. Verslijpe, M. Depierreux et al., Neurotensin high affinity binding sites and endopeptidase 24.11 are present respectively in the meningothelial and in the fibroblastic components of human meningiomas, Peptides, vol.11, issue.6, pp.1245-53, 1990.
DOI : 10.1016/0196-9781(90)90159-3

@. Maoret, J. Anini, Y. Rouyer-fessard, C. Gully, D. Laburthe et al., Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice, International Journal of Cancer, vol.317, issue.3, pp.448-54, 1999.
DOI : 10.1016/0014-5793(93)81509-X

@. Mazella, J. Vincent, and J. , Functional roles of the NTS2 and NTS3 receptors. Peptides, pp.2469-75, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00171898

@. Mazella, J. Zsürger, N. Navarro, V. Chabry, J. Kaghad et al., The 100-kDa Neurotensin Receptor Is gp95/Sortilin, A Non-G-Protein-coupled Receptor, Journal of Biological Chemistry, vol.63, issue.41, pp.26273-26279, 1998.
DOI : 10.1074/jbc.273.6.3582

@. Melander, O. Maisel, A. Almgren, P. Manjer, J. Belting et al., Plasma Proneurotensin and Incidence of Diabetes, Cardiovascular Disease, Breast Cancer, and Mortality, JAMA, vol.308, issue.14, pp.1469-75, 2012.
DOI : 10.1001/jama.2012.12998

@. Mengel, M. Von-wasielewski, R. Wiese, B. Rüdiger, T. Müller-hermelink et al., Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial, The Journal of Pathology, vol.106, issue.3, pp.292-301, 2002.
DOI : 10.1093/ajcp/106.5.634

@. Mijatovic, T. Gailly, P. Mathieu, V. , D. Nève et al., Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration, Cell Oncol, vol.29, issue.4, pp.315-341, 2007.

@. Mistry, A. Vijayan, and E. , Neurotensin enhances estradiol induced DNA synthesis in immature rat uterus, Life Sciences, vol.36, issue.21, pp.2063-2070, 1985.
DOI : 10.1016/0024-3205(85)90457-6

G. Mittica, E. Ghisoni, G. Giannone, M. Aglietta, S. Genta et al., Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity, Oncotarget, vol.8, issue.52, pp.90532-90544, 2017.
DOI : 10.18632/oncotarget.20042

@. Moody, T. Carney, D. Korman, L. Gazdar, A. Minna et al., Neurotensin is produced by and secreted from classic small cell lung cancer cells, Life Sciences, vol.36, issue.18, pp.1727-1759, 1985.
DOI : 10.1016/0024-3205(85)90555-7

@. Moody, T. Chiles, J. Casibang, M. Moody, E. Chan et al., SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells, Peptides, vol.22, issue.1, pp.109-124, 2001.
DOI : 10.1016/S0196-9781(00)00362-4

@. Morgat, C. Mishra, A. Varshney, R. Allard, M. Fernandez et al., Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors, Journal of Nuclear Medicine, vol.55, issue.10, 2014.
DOI : 10.2967/jnumed.114.142000

@. Mulè, F. Serio, R. Postorino, and A. , Motility pattern of isolated rat proximal colon and excitatory action of neurotensin, European Journal of Pharmacology, vol.275, issue.2, pp.131-138, 1995.
DOI : 10.1016/0014-2999(94)00760-5

@. Najimi, M. Robert, J. Mallet, J. Rostène, W. Forgez et al., Neurotensin Induces Tyrosine Hydroxylase Gene Activation through Nitric Oxide and Protein Kinase C Signaling Pathways, Molecular Pharmacology, vol.62, issue.3, pp.647-53, 2002.
DOI : 10.1124/mol.62.3.647
URL : http://molpharm.aspetjournals.org/content/molpharm/62/3/647.full.pdf

@. Najimi, M. Souazé, F. Méndez, M. Hermans, E. Berbar et al., Activation of Receptor Gene Transcription Is Required to Maintain Cell Sensitization after Agonist Exposure, Journal of Biological Chemistry, vol.268, issue.34, pp.21634-21675, 1998.
DOI : 10.1111/j.1471-4159.1993.tb03250.x
URL : http://www.jbc.org/content/273/34/21634.full.pdf

@. Nci and N. , The Cancer Genome Atlas (TCGA) Data Portal Use Case Workshop, 2008.

@. Neijt, J. Engelholm, S. Tuxen, M. Sorensen, P. Hansen et al., Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer, Journal of Clinical Oncology, vol.18, issue.17, pp.3084-92, 2000.
DOI : 10.1200/JCO.2000.18.17.3084

@. Nemeroff, C. Bissette, G. Manberg, P. Osbahr, A. Breese et al., Neurotensin-induced hypothermia: Evidence for an interaction with dopaminergic systems and the hypothalamic-pituitary-thyroids axis, Brain Research, vol.195, issue.1, 1980.
DOI : 10.1016/0006-8993(80)90867-7

, Aug, vol.11195, issue.1, pp.69-84

@. Nemeroff, C. Bissette, G. Prange, A. Jr, P. Loosen et al., Neurotensin: Central nervous system effects of a hypothalamic peptide, Brain Research, vol.128, issue.3, pp.485-96, 1977.
DOI : 10.1016/0006-8993(77)90173-1

@. Nemeroff, C. Osbahr, A. Manberg, P. Ervin, G. Prange et al., Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine., Proceedings of the National Academy of Sciences, vol.76, issue.10, pp.5368-71, 1979.
DOI : 10.1073/pnas.76.10.5368

@. Ness, R. Cramer, D. Goodman, M. Kjaer, S. Mallin et al.,

, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies, Infertility Am J Epidemiol Feb, vol.1155, issue.3, pp.217-241, 2002.

@. Ngô, C. Brugier, C. Plancher, C. De-la-rochefordière, A. Alran et al., Gynecological Cancer Study Group of Institut Curie. Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: a comparative study in 363 patients

J. Eur and . Oncol, , pp.1237-1281, 2014.

@. Nouel, D. Sarret, P. Vincent, J. Mazella, J. Beaudet et al., Pharmacological, molecular and functional characterization of glial neurotensin receptors, Neuroscience, vol.94, issue.4, pp.1189-97, 1999.
DOI : 10.1016/S0306-4522(99)00354-1

@. Nykjaer, A. Willnow, and T. , Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci, 2012.

R. Oakley, S. Laporte, J. Holt, L. Barak, and M. Caron, Journal of Biological Chemistry, vol.226, issue.22, pp.19452-60, 2001.
DOI : 10.1126/science.283.5402.655

@. Obata, K. Morland, S. Watson, R. Hitchcock, A. Chenevix-trench et al., Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res, pp.2095-2102, 1998.

@. Olsen, C. Nagle, C. Whiteman, D. Ness, R. Pearce et al., Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium, Endocrine-Related Cancer, vol.9, issue.1, pp.251-62, 2013.
DOI : 10.1002/ijc.24091

@. Orbo, A. Nilsen, M. Arnes, M. Pettersen, I. Larsen et al., Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial hyperplasia, Int J Gynecol Pathol, vol.22, issue.2, pp.141-149, 2003.

@. Oreskovic, S. Babic, D. Kalafatic, D. Barisic, D. Beketic-oreskovic et al., A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma, Gynecologic Oncology, vol.93, issue.1, pp.34-40, 2004.
DOI : 10.1016/j.ygyno.2003.12.038

@. Osadchii and O. , Emerging role of neurotensin in regulation of the cardiovascular system, European Journal of Pharmacology, vol.762, pp.184-92, 2015.
DOI : 10.1016/j.ejphar.2015.05.025

@. Ouyang, Q. Gong, X. Xiao, H. Zhou, J. Xu et al., Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients. Mol Cancer, Feb, vol.314, 2015.

@. Oza, A. Cook, A. Pfisterer, J. Embleton, A. Ledermann et al., ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results

, Lancet Oncol, vol.16, issue.8, pp.928-964, 2015.

@. Palacios, J. Gamallo, and C. , Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas, Cancer Res, vol.58, issue.7, pp.1344-1351, 1998.

@. Palles, C. Cazier, J. Howarth, K. Domingo, E. Jones et al., Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas, Nature Genetics, vol.98, issue.2, pp.136-180, 2012.
DOI : 10.1093/bioinformatics/btp253

@. Parazzini, F. , L. Vecchia, C. Negri, E. Riboldi et al., Diabetes and endometrial cancer: An Italian case-control study, International Journal of Cancer, vol.89, issue.4, pp.539-581, 1999.
DOI : 10.1002/(SICI)1097-0215(19990517)81:4<539::AID-IJC6>3.0.CO;2-Q

@. Parmar, M. Ledermann, J. Colombo, N. Du-bois, A. Delaloye et al., Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, pp.2099-106, 2003.

@. Pearce, C. Templeman, C. Rossing, M. Lee, A. Near et al., Berchuck A; Ovarian Cancer Association Consortium. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies, Lancet Oncol, vol.13, issue.411, pp.2012385-94, 1016.

, Epub, 2012.

@. Perren, T. Swart, A. Pfisterer, J. Ledermann, J. Pujade-lauraine et al., A Phase 3 Trial of Bevacizumab in Ovarian Cancer, Oza AM; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer, pp.2484-96, 1056.
DOI : 10.1056/NEJMoa1103799

@. Petru, E. Lück, H. Stuart, G. Gaffney, D. Millan et al., Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system, European Journal of Obstetrics & Gynecology and Reproductive Biology, vol.143, issue.2, pp.69-74, 2009.
DOI : 10.1016/j.ejogrb.2008.12.015

@. Pettibone, D. Totaro, and J. , High affinity binding of [3H]neurotensin of rat uterus. Peptides, pp.1169-72, 1987.

@. Pfisterer, J. Plante, M. Vergote, I. Du-bois, A. Hirte et al.,

N. Gcg, Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J Clin Oncol, vol.24, issue.29, pp.4699-707, 2006.

@. Pohlert and T. , The Pariwaise Multiple Comparison of Mean Ranks Package (PMCMR). R package, 2014.

@. Prat, J. Figo-committee-on-gynecologic, and . Oncology, FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication, J Gynecol Oncol. 2015, vol.26, issue.2

@. Prat, J. Figo-committee-on-gynecologic, and . Oncology, Staging classification for cancer of the ovary, fallopian tube, and peritoneum, Int J Gynaecol Obstet. 2014, vol.124, issue.1, 2013.

@. Pujade-lauraine, E. Hilpert, F. Weber, B. Reuss, A. Poveda et al., Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer, Obstetrical & Gynecological Survey, vol.69, issue.7
DOI : 10.1097/01.ogx.0000452705.82050.e4

, Clin Oncol, vol.32, issue.13, pp.1302-1310, 2014.

@. Pujade-lauraine, E. Wagner, U. Aavall-lundqvist, E. Gebski, V. Heywood et al., Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse, Journal of Clinical Oncology, vol.28, issue.20, pp.3323-3332, 2010.
DOI : 10.1200/JCO.2009.25.7519

@. Purdie, D. Bain, C. Webb, P. Whiteman, D. Pirozzo et al., Body size and ovarian cancer: case-control study and systematic review (Australia). Cancer Causes Control, pp.855-63, 2001.

@. and C. Team, R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2015.

M. @bullet-reinecke and . Neurotensin, Immunohistochemical localization in central and peripheral nervous system and in endocrine cells and its functional role as neurotransmitter and endocrine hormone, Prog Histochem Cytochem, vol.16, issue.1, pp.1-172, 1985.

@. Rice, M. Murphy, M. Tworoger, and S. , Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis, Journal of Ovarian Research, vol.5, issue.1, pp.13-23, 2012.
DOI : S1047279701002137
URL : http://doi.org/10.1186/1757-2215-5-13

H. @bullet-risch, L. Marrett, and G. Howe, Parity, Contraception, Infertility, and the Risk of Epithelial Ovarian Cancer, American Journal of Epidemiology, vol.140, issue.7, pp.585-97, 1994.
DOI : 10.1093/oxfordjournals.aje.a117296

H. @bullet-risch, J. Mclaughlin, D. Cole, B. Rosen, L. Bradley et al., Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer, The American Journal of Human Genetics, vol.68, issue.3, pp.700-710, 2001.
DOI : 10.1086/318787

I. @bullet-rizzuto, R. Behrens, and L. Smith, Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility

C. Database and S. Rev, , 2013.

@. Rodriguez, Y. Almeida, T. Valladares, F. Baez, D. Montes-de-oca et al., Neurotensin and neurotensin receptor 1 expression in human myometrium and uterine leiomyomas

, Biol Reprod, vol.83, issue.4, pp.641-648, 2010.

@. Rodriguez, Y. Baez, D. De-oca, F. Garcia, C. Dorta et al., Comparative Analysis of the ER??/ER?? Ratio and Neurotensin and its High-affinity Receptor in Myometrium, Uterine Leiomyoma, Atypical Leiomyoma, and Leiomyosarcoma, International Journal of Gynecological Pathology, vol.30, issue.4, pp.354-63, 2011.
DOI : 10.1097/PGP.0b013e31820918cb

W. @bullet-rostène and M. Alexander, Neurotensin and Neuroendocrine Regulation, Frontiers in Neuroendocrinology, vol.18, issue.2, pp.115-73, 1997.
DOI : 10.1006/frne.1996.0146

K. @bullet-rouibi and P. Rompré, Role of context in neurotensin-induced sensitization to the locomotor stimulant effect of amphetamine. Peptides, 2014.

N. @bullet-ryan, D. Evans, K. Green, and E. Crosbie, Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer, Gynecologic Oncology, vol.144, issue.3, pp.491-495, 2017.
DOI : 10.1016/j.ygyno.2017.01.005

@. Saada, S. Marget, P. Fauchais, A. Lise, M. Chemin et al., Differential Expression of Neurotensin and Specific Receptors, NTSR1 and NTSR2, in Normal and Malignant Human B Lymphocytes, The Journal of Immunology, vol.189, issue.11, pp.5293-303, 2012.
DOI : 10.4049/jimmunol.1102937
URL : https://hal.archives-ouvertes.fr/hal-00872646

@. Sakumoto, R. Hayashi, K. Saito, S. Kanahara, H. Kizaki et al., Comparison of the global gene expression profiles in the bovine endometrium between summer and autumn, Journal of Reproduction and Development, vol.61, issue.4, pp.297-3032015, 2015.
DOI : 10.1262/jrd.2015-024

@. Salvesen, H. Iversen, O. Akslen, and L. , Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas, Clin Cancer Res Off J Am Assoc Cancer Res, vol.4, issue.11, pp.2779-85, 1998.

@. Salvesen, H. Iversen, O. Akslen, and L. , Expression: A Population-Based Endometrial Carcinoma Study, Journal of Clinical Oncology, vol.17, issue.5, pp.1382-90, 1999.
DOI : 10.1200/JCO.1999.17.5.1382

@. Samartzis, E. Noske, A. Dedes, K. Fink, D. Imesch et al., ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas, International Journal of Molecular Sciences, vol.3, issue.9, pp.18824-18873, 2013.
DOI : 10.7150/jca.4140

@. Seethalakshmi, L. Mitra, S. Dobner, P. Menon, M. Carraway et al., Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations, The Prostate, vol.12, issue.3, pp.183-92, 1997.
DOI : 10.1016/0196-9781(91)90066-X

C. Sénéchal, E. Cottereau, A. De-pauw, C. Elan, I. Dagousset et al., Environmental and genetic risk factors for endometrial carcinoma]. Bull Cancer, pp.256-69, 2015.

@. Setiawan, V. Yang, H. Pike, M. Mccann, S. Yu et al., Type I and II Endometrial Cancers: Have They Different Risk Factors?, Journal of Clinical Oncology, vol.31, issue.20, pp.312607-312625, 2013.
DOI : 10.1200/JCO.2012.48.2596

@. Shapiro, S. Kelly, J. Rosenberg, L. Kaufman, D. Helmrich et al., Risk of Localized and Widespread Endometrial Cancer in Relation to Recent and Discontinued Use of Conjugated Estrogens, New England Journal of Medicine, vol.313, issue.16, pp.969-7210, 1056.
DOI : 10.1056/NEJM198510173131601

@. Shapiro, S. Kelly, J. Rosenberg, L. Kaufman, D. Helmrich et al., Risk of Localized and Widespread Endometrial Cancer in Relation to Recent and Discontinued Use of Conjugated Estrogens, New England Journal of Medicine, vol.313, issue.16, pp.969-72, 1985.
DOI : 10.1056/NEJM198510173131601

@. Shi, L. Wu, Y. Li, and C. , Hormone therapy and risk of ovarian cancer in postmenopausal women, Menopause, vol.23, issue.4, pp.417-441
DOI : 10.1097/GME.0000000000000550

@. Shimizu, S. Tsukada, J. Sugimoto, T. Kikkawa, N. Sasaki et al., Identification of a novel therapeutic target for head and neck squamous cell carcinomas: A role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway, International Journal of Cancer, vol.12, issue.8, pp.1816-1839, 2008.
DOI : 10.1152/ajpcell.00328.2002

@. Simpkins, F. Drake, R. Escobar, P. Nutter, B. Rasool et al., A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA), Gynecologic Oncology, vol.136, issue.2, 2014.
DOI : 10.1016/j.ygyno.2014.12.004

@. Singer, G. Oldt, R. Cohen, Y. Wang, B. Sidransky et al., Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma, JNCI Journal of the National Cancer Institute, vol.61, issue.10, pp.484-490, 2003.
DOI : 10.1097/00000478-199906000-00001

@. Soler, M. Chatenoud, L. Negri, E. Parazzini, F. Franceschi et al., Hypertension and Hormone-Related Neoplasms in Women, Hypertension, vol.34, issue.2, pp.320-325, 1979.
DOI : 10.1161/01.HYP.34.2.320

@. Somaï, S. Gompel, A. Rostène, W. Forgez, and P. , Neurotensin counteracts apoptosis in breast cancer cells, Biochemical and Biophysical Research Communications, vol.295, issue.2, pp.482-490, 2002.
DOI : 10.1016/S0006-291X(02)00703-9

@. Sorbye, S. Kilvaer, T. Valkov, A. Donnem, T. Smeland et al., Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft Tissue Sarcomas, PLoS ONE, vol.7, issue.10, 2012.
DOI : 10.1371/journal.pone.0047068.t006

@. Souazé, F. Dupouy, S. Viardot-foucault, V. Bruyneel, E. Attoub et al., Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression, Cancer Research, vol.66, issue.12, pp.6243-6252, 2006.
DOI : 10.1158/0008-5472.CAN-06-0450

@. Souazé, F. Forgez, and P. , Molecular and cellular regulation of neurotensin receptor under acute and chronic agonist stimulation. Peptides, pp.2493-501, 2006.

@. Souazé, F. Rostène, W. Forgez, and P. , Neurotensin Agonist Induces Differential Regulation of Neurotensin Receptor mRNA, Journal of Biological Chemistry, vol.7, issue.15, pp.10087-94, 1997.
DOI : 10.1016/0196-9781(86)90136-1

@. Souaze, F. Viardot-foucault, V. Roullet, N. Toy-miou-leong, M. Gompel et al., Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas Vascular proliferation is important for clinical progress of endometrial cancer, Carcinogenesis. Cancer Res, vol.2766, issue.46, pp.708-7163303, 2006.

@. Strosberg, J. Nasir, A. Hodul, P. Kvols, and L. , Biology and treatment of metastatic gastrointestinal neuroendocrine tumors, Gastrointest Cancer Res GCR, vol.2, issue.3, pp.113-138, 2008.

@. Swift, S. Burns, J. Maitland, and N. , Altered Expression of Neurotensin Receptors Is Associated with the Differentiation State of Prostate Cancer, Cancer Research, vol.70, issue.1, pp.347-56, 2010.
DOI : 10.1158/0008-5472.CAN-09-1252

@. Tanaka, K. Masu, M. Nakanishi, and S. , Structure and functional expression of the cloned rat neurotensin receptor, Neuron, vol.4, issue.6, pp.847-54, 1990.
DOI : 10.1016/0896-6273(90)90137-5

@. Tanaka, T. Knapp, D. Nasmyth, and K. , Loading of an Mcm protein onto DNA replication origins is regulated by Cdc6p and CDKs. Cell, pp.649-60, 1997.

@. Tang, K. Ma, S. Lee, T. Chan, Y. Kwan et al., CD133+ liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling, Hepatology, vol.27, issue.9, pp.807-827, 2012.
DOI : 10.1016/j.peptides.2006.01.028
URL : http://onlinelibrary.wiley.com/doi/10.1002/hep.24739/pdf

@. Taylor, R. Severns, V. Brown, D. Bisoffi, M. Sillerud et al., Prostate cancer targeting motifs: Expression of ??????3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts, The Prostate, vol.3, issue.4, pp.523-555, 2012.
DOI : 10.1038/ncpuro0452
URL : http://europepmc.org/articles/pmc4366051?pdf=render

@. Theodorsson-norheim, E. Rosell, and S. , Characterization of human plasma neurotensin-like immunoreactivity after fat ingestion. Regul Pept, pp.207-225, 1983.
DOI : 10.1016/0167-0115(83)90139-8

@. Therneau and T. , A Package for Survival Analysis in S_. version 2.38, 2015.

@. Thigpen, J. Brady, M. Homesley, H. Malfetano, J. Dubeshter et al., Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study, Journal of Clinical Oncology, vol.22, issue.19, 2004.
DOI : 10.1200/JCO.2004.02.088

, Oct, vol.122, pp.3902-3910

@. Thigpen, T. Dubois, A. Mcalpine, J. Disaia, P. Fujiwara et al., First-Line Therapy in Ovarian Cancer Trials, International Journal of Gynecological Cancer, vol.21, issue.4, pp.756-62, 2011.
DOI : 10.1097/IGC.0b013e31821ce75d

@. Tomao, F. , L. Russo, G. Spinelli, G. Stati et al., Fertility drugs, reproductive strategies and ovarian cancer risk, Journal of Ovarian Research, vol.7, issue.1, pp.51-61, 1757.
DOI : 10.1016/j.critrevonc.2009.12.005

@. Törnberg, S. Carstensen, and J. , Relationship between Quetelet's index and cancer of breast and female genital tract in 47,000 women followed for 25 years, British Journal of Cancer, vol.69, issue.2, pp.358-61, 1994.
DOI : 10.1038/bjc.1994.65

@. Toss, A. Tomasello, C. Razzaboni, E. Contu, G. Grandi et al., Hereditary ovarian cancer: not only BRCA 1 and 2 genes, Biomed Res Int, vol.2015, pp.341723-341733, 0109.

@. Toy-miou-leong, M. Cortes, C. Beaudet, A. Rostène, W. Forgez et al., Receptor Trafficking via the Perinuclear Recycling Compartment Accompanied by Cell Division Is Necessary for Permanent Neurotensin Cell Sensitization and Leads to Chronic Mitogen-activated Protein Kinase Activation, Journal of Biological Chemistry, vol.6, issue.13, pp.12636-12682, 2003.
DOI : 10.1006/excr.2001.5421

B. @bullet-trétarre, F. Molinié, A. Woronoff, N. Bossard, F. Bessaoud et al., Ovarian cancer in France: Trends in incidence, mortality and survival, 1980???2012, Gynecologic Oncology, vol.139, issue.2, pp.324-333, 2015.
DOI : 10.1016/j.ygyno.2015.09.013

@. Turner, J. James-kracke, M. Camden, and J. , Regulation of the neurotensin receptor and intracellular calcium mobilization in HT29 cells, J Pharmacol Exp Ther, vol.253, issue.3, pp.1049-56, 1990.

@. Tye and B. , MCM Proteins in DNA Replication, Annual Review of Biochemistry, vol.68, issue.1, pp.649-86, 1999.
DOI : 10.1146/annurev.biochem.68.1.649

@. Ulich, T. Cheng, L. Glover, H. Yang, K. Lewin et al., A colonic adenocarcinoma with argentaffin cells. An immunoperoxidase study demonstrating the presence of numerous neuroendocrine products. Cancer, pp.1483-1492, 1983.

@. Umezu, K. Hiradate, Y. Oikawa, T. Ishiguro, H. Numabe et al., Exogenous neurotensin modulates sperm function in Japanese Black cattle, Journal of Reproduction and Development, vol.62, issue.4, 2016.
DOI : 10.1262/jrd.2016-055

@. Ushiro, S. Mizoguchi, K. Yoshida, S. Jimi, S. Fujiwara et al., Stimulation of cell-surface urokinase-type plasminogen activator activity and cell migration in vascular endothelial cells by a novel hexapeptide analogue of neurotensin, FEBS Letters, vol.15, issue.3, pp.341-346, 1997.
DOI : 10.1016/0165-6147(94)90130-9

@. Valerie, N. Casarez, E. Dasilva, J. Dunlap-brown, M. Parsons et al., Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Cancer Res, Nov, vol.171, issue.21, pp.6817-6843, 2011.

@. Van-wijk, F. Aapro, M. Bolis, G. Chevallier, B. Van-der-burg et al., European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group, Ann Oncol, 2003.

@. Vandenbulcke, F. Nouel, D. Vincent, J. Mazella, J. Beaudet et al., Ligand-induced internalization of neurotensin in transfected COS-7 cells: differential intracellular trafficking of ligand and receptor, J Cell Sci, vol.113, pp.2963-75, 2000.

@. Vang, R. , S. Iem, and R. Kurman, Ovarian Low-grade and High-grade Serous Carcinoma, Advances in Anatomic Pathology, vol.16, issue.5, pp.267-82, 2009.
DOI : 10.1097/PAP.0b013e3181b4fffa

@. Vergote, I. Amant, F. Kristensen, G. Ehlen, T. Reed et al., Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer, European Journal of Cancer, vol.47, issue.11, pp.88-92, 2011.
DOI : 10.1016/S0959-8049(11)70152-6

C. Vigouroux, J. Casse, S. Battaglia-hsu, L. Brochin, A. Luc et al., Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma. Lung Cancer Amst Neth, 2015.
DOI : 10.1016/j.lungcan.2015.05.008

@. Vijayan, E. Mistry, and A. , Anti-implantation role for substance P and neurotensin in rat, Indian J Exp Biol, 1992.

, Feb, vol.30, issue.2, pp.80-82

@. Vincent, J. Mazella, J. Kitabgi, and P. , Neurotensin and neurotensin receptors, Trends in Pharmacological Sciences, vol.20, issue.7, pp.302-311, 1999.
DOI : 10.1016/S0165-6147(99)01357-7
URL : https://hal.archives-ouvertes.fr/hal-00171827

@. Vita, N. Laurent, P. Lefort, S. Chalon, P. Dumont et al., Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor, FEBS Letters, vol.140, issue.1-2, pp.139-181, 1993.
DOI : 10.1016/0014-2999(87)90285-8

@. Wang, H. Wu, and T. , mediates neurotensin excitation of substantia nigra dopaminergic neurons, Molecular Brain Research, vol.36, issue.1, pp.29-36, 1996.
DOI : 10.1016/0169-328X(95)00235-K

@. Wang, J. Li, N. Li, H. Cui, L. Wang et al., Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1, Neuropeptides, vol.45, issue.2, pp.151-157, 2011.
DOI : 10.1016/j.npep.2011.01.002

@. Wang, X. Wang, Q. Ives, K. Evers, and B. , Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin Cancer Res, pp.5346-55, 2006.
DOI : 10.1158/1078-0432.ccr-06-0968
URL : http://clincancerres.aacrjournals.org/content/12/18/5346.full.pdf

@. Watters, J. Dorsa, and D. , Transcriptional Effects of Estrogen on Neuronal Neurotensin Gene Expression Involve cAMP/Protein Kinase A-Dependent Signaling Mechanisms, The Journal of Neuroscience, vol.18, issue.17, pp.6672-80, 1998.
DOI : 10.1523/JNEUROSCI.18-17-06672.1998

@. Win, A. Reece, J. Ryan, and S. , Family History and Risk of Endometrial Cancer, Obstetrics & Gynecology, vol.125, issue.1
DOI : 10.1097/AOG.0000000000000563

, Obstet Gynecol. 2015, vol.125, issue.1, pp.89-98

@. Who, WHO classification of tumours of female reproductive organs, 2014.

@. Wu, Z. Martinez-fong, D. Tredaniel, J. Forgez, and P. , Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy, Frontiers in Endocrinology, vol.3
DOI : 10.3389/fendo.2012.00184

@. Yamashita, Y. Akatsuka, S. Shinjo, K. Yatabe, Y. Kobayashi et al., Met Is the Most Frequently Amplified Gene in Endometriosis-Associated Ovarian Clear Cell Adenocarcinoma and Correlates with Worsened Prognosis, PLoS ONE, vol.18, issue.3, 2013.
DOI : 10.1371/journal.pone.0057724.s003

Y. @bullet-ye, X. Long, L. Zhang, J. Chen, P. Liu et al., NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/?-catenin signaling pathway in hepatocellular carcinoma, Oncotarget, vol.7, issue.43, pp.70303-70322, 2016.

@. You, Z. Komamura, Y. Ishimi, and Y. , Biochemical Analysis of the Intrinsic Mcm4-Mcm6-Mcm7 DNA Helicase Activity, Molecular and Cellular Biology, vol.19, issue.12, pp.8003-8018, 1999.
DOI : 10.1128/MCB.19.12.8003
URL : https://mcb.asm.org/content/mcb/19/12/8003.full.pdf

@. Younes, M. Wu, Z. Dupouy, S. Lupo, A. Mourra et al., Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib, Oncotarget, vol.5, issue.18, pp.8252-69, 2014.
DOI : 10.18632/oncotarget.1633
URL : http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=1633&path%5B%5D=4619

D. Zhao, S. Kuhnt-moore, H. Zeng, J. Wu, M. Moyer et al., Neurotensin stimulates IL-8 expression in human colonic epithelial cells through Rho GTPase-mediated NF-kappa B pathways, Am J Physiol Cell Physiol, 2003.
DOI : 10.1152/ajpcell.00328.2002

, Epub, vol.284, issue.6, pp.1397-404, 2003.

@. Zhao, D. Zhan, Y. Koon, H. Zeng, H. Keates et al., Metalloproteinase-dependent Transforming Growth Factor-?? Release Mediates Neurotensin-stimulated MAP Kinase Activation in Human Colonic Epithelial Cells, Journal of Biological Chemistry, vol.279, issue.42, pp.43547-54, 2004.
DOI : 10.1074/jbc.M401453200

, Annexe 1 : Publications A. Manuscrit 1

, Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome

M. Agopiantz, P. Forgez, J. Casse, S. Lacomme, C. Charra-brunaud et al.,

, Neurotensin receptor 1 antagonist SR48692 improves response to carboplatin by enhancing apoptosis and inhibiting drug efflux in ovarian cancer

J. Liu, M. Agopiantz, J. Poupon, Z. Wu, P. Just et al.,

J. Hotton, M. Agopiantz, A. Leroux, C. Charra-brunaud, M. B. Busby-venner et al., Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma. Virchows Arch, p.29243125, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01932031

D. Cordary, A. Braconier, F. Guillet-may, O. Morel, M. Agopiantz et al., Immobilization versus immediate mobilization after intrauterine insemination: A systematic review and meta-analysis, 005. [Epub ahead of print] Review, pp.2468-7847, 2017.
DOI : 10.1016/j.jogoh.2017.09.005

M. Agopiantz, P. Forgez, J. Casse, S. Lacomme, C. Charra-brunaud et al., Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome. Virchows Arch, p.28836043, 2017.

J. Liu, M. Agopiantz, J. Poupon, Z. Wu, P. Just et al., Neurotensin receptor 1 antagonist SR48692 improves response to carboplatin by enhancing apoptosis and inhibiting drug efflux in ovarian cancer. Clin Cancer Res, p.28790113, 2017.

H. Minebois, D. Souza, A. Mezan-de-malartic, C. Agopiantz, M. et al., Endometriosis and miscarriage: Systematic review], Gynecol Obstet Fertil Senol, vol.17, pp.2468-7189, 2017.

M. Agopiantz, L. Xandre-rodriguez, J. B. Urbistondoy, G. Ialy-radio, C. Chalbi et al., Growth arrest specific 1 (Gas1) and glial cell line-derived neurotrophic factor receptor ??1 (Gfr??1), two mouse oocyte glycosylphosphatidylinositol-anchored proteins, are involved in fertilisation, Reproduction, Fertility and Development, vol.29, issue.4, pp.824-837
DOI : 10.1071/RD15367

J. Faivre, J. Bibault, T. Leroy, M. Agopiantz, J. Salleron et al., Evaluation of the Theoretical Teaching of Postgraduate Radiation Oncology Medical Residents in France: a Cross-Sectional Study, Journal of Cancer Education, vol.103, issue.2, p.28138918, 2017.
DOI : 10.1016/j.radonc.2012.03.006

M. Agopiantz, P. Journeau, B. Lebon-labich, A. Sorlin, T. Cuny et al., McCune-Albright syndrome, natural history and multidisciplinary management in a series of 14 pediatric cases 2016 Feb, Ann Endocrinol, vol.77, issue.1, p.26850292

M. Agopiantz, O. Elhanbali, B. Demore, T. Cuny, L. Demarquet et al., Thyroid side effects prophylaxis in front of nuclear power plant accidents, Annales d'Endocrinologie, vol.77, issue.1
DOI : 10.1016/j.ando.2015.12.003
URL : https://hal.archives-ouvertes.fr/hal-01474292

, 2016 Feb, Review, vol.77, issue.1, pp.1-6, 2016.

J. Faivre, M. Agopiantz, E. Loeb, K. Cassinari, M. Wack et al., [Evaluation of the theoretical teaching of postgraduate medical students in France], Rev Med Interne, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01812576

M. Agopiantz, F. Scheffler, J. Faivre, S. Bonne, P. Catoire et al., Enseignement th??orique du Dipl??me d?????tudes sp??cialis??es de gyn??cologie m??dicale en France??: ??valuation nationale, Gyn??cologie Obst??trique & Fertilit??, vol.43, issue.1, pp.25-32, 2014.
DOI : 10.1016/j.gyobfe.2014.11.006

A. Collet, J. Chatelin, M. Agopiantz, M. Valduga, C. Bonnet et al., An adult patient with 49, XXXXY syndrome: further clinical and biological delineation], Ann Biol Clin, vol.72, issue.3, pp.371-378, 2014.

M. Agopiantz, P. Corbonnois, A. Sorlin, C. Bonnet, M. Klein et al., Endocrine disorders in Woodhouse-Sakati syndrome: a systematic review of the literature, Journal of Endocrinological Investigation, vol.433, issue.7021, pp.1-7, 2014.
DOI : 10.1038/nature03207
URL : https://hal.archives-ouvertes.fr/hal-01688744

L. Chatton, M. Zaccabri, A. Agopiantz, M. Leheup, B. Weryha et al., Azoospermie et mosa??que 45,X/46,XY??: ?? propos d???un cas, Gyn??cologie Obst??trique & Fertilit??, vol.41, issue.3, pp.203-209, 2013.
DOI : 10.1016/j.gyobfe.2013.01.007

M. Agopiantz, B. Birène, and F. Scheffler, Demographic status and perspectives in medical gynecology in France in 2012], Gynecol Obstet Fertil, vol.41, issue.3, p.23498727, 2013.

F. Scheffler, M. Agopiantz, L. Chatton, M. Swierkowski-blanchard, and N. , Focusing on young medical gynecologists future in 2012], Gynecol Obstet Fertil, 2013.

F. Coussy and M. Agopiantz, Medical gynaecology in France: a specific training program]. Gynecol Obstet Fertil, p.20189437, 2010.